$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

$fold Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000117887921000004 Filed on March 01, 2021

Income Statement

Concept	2020 Q4	2019 Q4	2019 Q3
Revenue	$70.57M	$55.29M	$48.77M
YoY Change	27.63%	69.38%	136.78%
Cost Of Revenue	$9.420M	$6.950M	$5.596M
YoY Change	35.54%	60.14%	29.84%
Gross Profit	$61.15M	$48.35M	$43.17M
YoY Change	26.47%	70.85%	165.09%
Gross Profit Margin	86.65%	87.44%	88.53%
Selling, General & Admin	$43.69M	$43.30M	$39.68M
YoY Change	0.9%	11.68%	24.52%
% of Gross Profit	71.45%	89.56%	91.91%
Research & Development	$79.29M	$91.91M	$58.89M
YoY Change	-13.73%	60.63%	-57.39%
% of Gross Profit	129.66%	190.09%	136.41%
Depreciation & Amortization	$2.550M	$1.520M	$1.116M
YoY Change	67.76%	26.67%	4.01%
% of Gross Profit	4.17%	3.14%	2.59%
Operating Expenses	$126.0M	$137.4M	$100.5M
YoY Change	-8.28%	40.47%	-41.74%
Operating Profit	-$64.84M	-$89.02M	-$57.31M
YoY Change	-27.16%	28.1%	-63.31%
Interest Expense	-$7.950M	-$1.510M	$4.026M
YoY Change	426.49%	-72.79%	-14.61%
% of Operating Profit
Other Income/Expense, Net	-$810.0K	$650.0K	-$3.481M
YoY Change	-224.62%	-131.86%	235.03%
Pretax Income	-$73.59M	-$89.89M	-$62.06M
YoY Change	-18.13%	16.63%	-61.02%
Income Tax	-$2.190M	-$160.0K	-$251.0K
% Of Pretax Income
Net Earnings	-$71.40M	-$89.73M	-$61.81M
YoY Change	-20.43%	14.91%	-61.17%
Net Earnings / Revenue	-101.18%	-162.28%	-126.74%
Basic Earnings Per Share
Diluted Earnings Per Share	-$273.4K	-$351.7K	-$242.7K
COMMON SHARES
Basic Shares Outstanding	260.6M shares	254.8M shares	254.6M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q4	2019 Q4	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$483.3M	$452.7M	$514.2M
YoY Change	6.76%	-10.21%	-8.89%
Cash & Equivalents	$163.2M	$142.8M	$166.3M
Short-Term Investments	$320.0M	$309.9M	$347.9M
Other Short-Term Assets	$29.70M	$20.00M	$19.60M
YoY Change	48.5%	20.48%	20.99%
Inventory	$19.56M	$14.04M	$9.154M
Prepaid Expenses
Receivables	$46.92M	$33.28M	$33.73M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$579.5M	$520.1M	$576.7M
YoY Change	11.42%	-5.63%	-4.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$43.86M	$47.71M	$34.67M
YoY Change	-8.05%	319.38%	225.29%
Goodwill	$197.8M	$197.8M	$197.8M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$23.00M	$23.00M	$23.00M
YoY Change	0.0%	0.0%	0.0%
Long-Term Investments
YoY Change
Other Assets	$19.10M	$28.32M	$14.35M
YoY Change	-32.57%	323.72%	135.3%
Total Long-Term Assets	$307.1M	$330.1M	$305.6M
YoY Change	-6.99%	38.22%	28.66%
TOTAL ASSETS
Total Short-Term Assets	$579.5M	$520.1M	$576.7M
Total Long-Term Assets	$307.1M	$330.1M	$305.6M
Total Assets	$886.5M	$850.2M	$882.3M
YoY Change	4.27%	7.63%	5.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.06M	$21.72M	$81.50M
YoY Change	-21.45%	228.82%	50.09%
Accrued Expenses	$103.7M	$7.200M	$6.400M
YoY Change	1340.28%
Deferred Revenue	$0.00	$4.000M
YoY Change	-100.0%	-55.56%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$129.7M	$128.8M	$93.08M
YoY Change	0.67%	49.56%	41.29%
LONG-TERM LIABILITIES
Long-Term Debt	$389.3M	$149.5M	$149.3M
YoY Change	160.4%	-53.53%	-53.17%
Other Long-Term Liabilities	$6.379M	$5.296M	$4.591M
YoY Change	20.45%	85.63%	51.57%
Total Long-Term Liabilities	$6.379M	$5.296M	$4.591M
YoY Change	20.45%	85.63%	51.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$129.7M	$128.8M	$93.08M
Total Long-Term Liabilities	$6.379M	$5.296M	$4.591M
Total Liabilities	$600.1M	$373.8M	$334.0M
YoY Change	60.56%	-16.39%	-21.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.045B	-$1.769B	-$1.700B
YoY Change	15.65%	25.24%	27.42%
Common Stock	$2.311B	$2.230B	$2.213B
YoY Change	3.65%	28.0%	27.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$286.4M	$476.4M	$548.3M
YoY Change
Total Liabilities & Shareholders Equity	$886.5M	$850.2M	$882.3M
YoY Change	4.27%	7.63%	5.21%

Cashflow Statement

Concept	2020 Q4	2019 Q4	2019 Q3
OPERATING ACTIVITIES
Net Income	-$71.40M	-$89.73M	-$61.81M
YoY Change	-20.43%	14.91%	-61.17%
Depreciation, Depletion And Amortization	$2.550M	$1.520M	$1.116M
YoY Change	67.76%	26.67%	4.01%
Cash From Operating Activities	-$49.82M	-$57.84M	-$55.55M
YoY Change	-13.87%	-4.68%	-58.16%
INVESTING ACTIVITIES
Capital Expenditures	-$1.070M	-$10.92M	-$3.980M
YoY Change	-90.2%	527.59%	47.96%
Acquisitions
YoY Change
Other Investing Activities	-$21.71M	$37.89M	$7.170M
YoY Change	-157.3%	-161.05%	-93.88%
Cash From Investing Activities	-$22.78M	$26.96M	$3.190M
YoY Change	-184.5%	-142.26%	-97.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	21.55M	3.190M	520.0K
YoY Change	575.55%	786.11%	-99.65%
NET CHANGE
Cash From Operating Activities	-49.82M	-57.84M	-55.55M
Cash From Investing Activities	-22.78M	26.96M	3.190M
Cash From Financing Activities	21.55M	3.190M	520.0K
Net Change In Cash	-51.05M	-27.69M	-51.84M
YoY Change	84.36%	-77.69%	-140.33%
FREE CASH FLOW
Cash From Operating Activities	-$49.82M	-$57.84M	-$55.55M
Capital Expenditures	-$1.070M	-$10.92M	-$3.980M
Free Cash Flow	-$48.75M	-$46.92M	-$51.57M
YoY Change	3.9%	-20.39%	-60.35%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	45604000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	53531000	USD
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001178879
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2017	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	us-gaap:AccountingStandardsUpdate201802Member
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-33497
CY2020	dei	Entity Registrant Name EntityRegistrantName	Amicus Therapeutics, Inc.
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	71-0869350
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	3675 Market Street,
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	Philadelphia,
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	19104
CY2020	dei	City Area Code CityAreaCode	(215)
CY2020	dei	Local Phone Number LocalPhoneNumber	921-7600
CY2020	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2020	dei	Trading Symbol TradingSymbol	FOLD
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	3851129284	USD
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	264316074	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	163240000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	142837000	USD
CY2020Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	320029000	USD
CY2019Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	309903000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	46923000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	33284000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	19556000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	14041000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	29721000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	20008000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	579469000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	520073000	USD
CY2020Q4	fold	Accumulated Depreciation Operating Right Of Use Leases AccumulatedDepreciationOperatingRightOfUseLeases	7574000	USD
CY2019Q4	fold	Accumulated Depreciation Operating Right Of Use Leases AccumulatedDepreciationOperatingRightOfUseLeases	5342000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23296000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	33315000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14487000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	17604000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43863000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	47705000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23000000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23000000	USD
CY2020Q4	us-gaap	Goodwill Goodwill	197797000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	197797000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	19095000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	28317000	USD
CY2020Q4	us-gaap	Assets Assets	886520000	USD
CY2019Q4	us-gaap	Assets Assets	850207000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17063000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	21722000	USD
CY2020Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	96841000	USD
CY2019Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	99901000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	8900000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	0	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6872000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7189000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	129676000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	128812000	USD
CY2020Q4	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	7406000	USD
CY2019Q4	us-gaap	Deferred Credits And Other Liabilities Noncurrent DeferredCreditsAndOtherLiabilitiesNoncurrent	8906000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	389254000	USD
CY2019Q4	us-gaap	Long Term Debt LongTermDebt	149505000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	16925000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	22681000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	4896000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	5051000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	45604000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	53531000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	6379000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	5296000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	600140000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	373782000	USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	262063461	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	262063461	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	255417869	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	255417869	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	2650000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	2598000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2308578000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2227225000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	8412000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	2785000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-185000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	40000	USD
CY2020Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	12387000	USD
CY2019Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	12387000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2045462000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1768610000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	286380000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	476425000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	886520000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	850207000	USD
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	260886000	USD
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	182237000	USD
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	91245000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	31044000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	21963000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	14404000	USD
CY2020	us-gaap	Gross Profit GrossProfit	229842000	USD
CY2019	us-gaap	Gross Profit GrossProfit	160274000	USD
CY2018	us-gaap	Gross Profit GrossProfit	76841000	USD
CY2020	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	308443000	USD
CY2019	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	286378000	USD
CY2018	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	270902000	USD
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	156407000	USD
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	169861000	USD
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	127200000	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-3144000	USD
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-3297000	USD
CY2018	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-3300000	USD
CY2020	us-gaap	Depreciation And Amortization DepreciationAndAmortization	8846000	USD
CY2019	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4775000	USD
CY2018	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4216000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	476840000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	464311000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	405618000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-246998000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-304037000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-328777000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	3226000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	10249000	USD
CY2018	us-gaap	Investment Income Interest InvestmentIncomeInterest	10461000	USD
CY2020	us-gaap	Interest Expense InterestExpense	22425000	USD
CY2019	us-gaap	Interest Expense InterestExpense	18872000	USD
CY2018	us-gaap	Interest Expense InterestExpense	22402000	USD
CY2020	fold	Gain Loss On Exchange Of Debt GainLossOnExchangeOfDebt	0	USD
CY2019	fold	Gain Loss On Exchange Of Debt GainLossOnExchangeOfDebt	-40624000	USD
CY2018	fold	Gain Loss On Exchange Of Debt GainLossOnExchangeOfDebt	0	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7276000	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	USD
CY2019	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	0	USD
CY2018	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-2739000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-781000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2626000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5632000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-274254000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-355910000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-349089000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2598000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	478000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-94000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-276852000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-356388000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-348995000	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.07
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.48
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.88
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	258867380	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	240421001	shares
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	185790021	shares
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-276852000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-356388000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-348995000	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	1552000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	889000	USD
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Translation Gain Loss Arising During Period Tax OtherComprehensiveIncomeForeignCurrencyTranslationGainLossArisingDuringPeriodTax	0	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	5627000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	2290000	USD
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	2537000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	-50000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	182000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax	0	USD
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-225000	USD
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	467000	USD
CY2018	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	9000	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	5402000	USD
CY2019	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2757000	USD
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2546000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-271450000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-353631000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-346449000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	352850000	USD
CY2018	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	9144000	USD
CY2018	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	294583000	USD
CY2018	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	2832000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	29260000	USD
CY2018	fold	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	3617000	USD
CY2018	fold	Adjustments To Additional Paid In Capital Change In Fair Value Of Derivatives AdjustmentsToAdditionalPaidInCapitalChangeInFairValueOfDerivatives	2739000	USD
CY2018	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	9000	USD
CY2018	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	2537000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-348995000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	342912000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	11476000	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	188994000	USD
CY2019	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3235000	USD
CY2019	fold	Stock Issued During Period Value Contingent Consideration StockIssuedDuringPeriodValueContingentConsideration	9316000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	44430000	USD
CY2019	fold	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	812000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	215476000	USD
CY2019	fold	Adjustments To Additional Paid In Capital Premiums Paid From Termination Of Capped Call Confirmations AdjustmentsToAdditionalPaidInCapitalPremiumsPaidFromTerminationOfCappedCallConfirmations	19875000	USD
CY2019	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	467000	USD
CY2019	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	2290000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-356388000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	476425000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	42282000	USD
CY2020	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	10028000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	49151000	USD
CY2020	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-225000	USD
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	5627000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-276852000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	286380000	USD
CY2020	us-gaap	Profit Loss ProfitLoss	-276852000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	-356388000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	-348995000	USD
CY2020	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1794000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2546000	USD
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	10976000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8846000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4775000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	4216000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	49151000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	44430000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	29260000	USD
CY2020	fold	Gain Loss On Exchange Of Debt GainLossOnExchangeOfDebt	0	USD
CY2019	fold	Gain Loss On Exchange Of Debt GainLossOnExchangeOfDebt	-40624000	USD
CY2018	fold	Gain Loss On Exchange Of Debt GainLossOnExchangeOfDebt	0	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-7276000	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	0	USD
CY2019	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	0	USD
CY2018	us-gaap	Fair Value Net Derivative Asset Liability Measured On Recurring Basis Change In Unrealized Gain Loss FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisChangeInUnrealizedGainLoss	-2739000	USD
CY2020	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	3144000	USD
CY2019	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	3297000	USD
CY2018	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	3300000	USD
CY2020	fold	Foreign Currency Remeasurement Gain Loss Before Tax ForeignCurrencyRemeasurementGainLossBeforeTax	-5471000	USD
CY2019	fold	Foreign Currency Remeasurement Gain Loss Before Tax ForeignCurrencyRemeasurementGainLossBeforeTax	-254000	USD
CY2018	fold	Foreign Currency Remeasurement Gain Loss Before Tax ForeignCurrencyRemeasurementGainLossBeforeTax	-3217000	USD
CY2020	fold	Non Cash Deferred Taxes And Other Tax Benefits NonCashDeferredTaxesAndOtherTaxBenefits	155000	USD
CY2019	fold	Non Cash Deferred Taxes And Other Tax Benefits NonCashDeferredTaxesAndOtherTaxBenefits	1415000	USD
CY2018	fold	Non Cash Deferred Taxes And Other Tax Benefits NonCashDeferredTaxesAndOtherTaxBenefits	0	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-99000	USD
CY2019	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	149000	USD
CY2018	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-59000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11219000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	11114000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	13294000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4639000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	5114000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4205000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8766000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3287000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2488000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-10610000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	46742000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	17115000	USD
CY2020	fold	Increase Decrease In Noncurrent Operating Liabilities IncreaseDecreaseInNoncurrentOperatingLiabilities	4420000	USD
CY2019	fold	Increase Decrease In Noncurrent Operating Liabilities IncreaseDecreaseInNoncurrentOperatingLiabilities	-10117000	USD
CY2018	fold	Increase Decrease In Noncurrent Operating Liabilities IncreaseDecreaseInNoncurrentOperatingLiabilities	-581000	USD
CY2020	fold	Increase Decrease In Deferred Reimbursements IncreaseDecreaseInDeferredReimbursements	-1250000	USD
CY2019	fold	Increase Decrease In Deferred Reimbursements IncreaseDecreaseInDeferredReimbursements	-5500000	USD
CY2018	fold	Increase Decrease In Deferred Reimbursements IncreaseDecreaseInDeferredReimbursements	-6250000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-233290000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-250416000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-299955000	USD
CY2020	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	354826000	USD
CY2019	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	499047000	USD
CY2018	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	463502000	USD
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	365178000	USD
CY2019	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	383882000	USD
CY2018	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	578394000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3227000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	20012000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	6308000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13579000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	95153000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-121200000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	188994000	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	294584000	USD
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	155249000	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2018	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2020	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	385929000	USD
CY2019	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0	USD
CY2018	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	146596000	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	76000	USD
CY2019	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	420000	USD
CY2018	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	334000	USD
CY2020	fold	Payments For Repurchase Of Restricted Stock Units PaymentsForRepurchaseOfRestrictedStockUnits	10028000	USD
CY2019	fold	Payments For Repurchase Of Restricted Stock Units PaymentsForRepurchaseOfRestrictedStockUnits	3235000	USD
CY2018	fold	Payments For Repurchase Of Restricted Stock Units PaymentsForRepurchaseOfRestrictedStockUnits	2832000	USD
CY2020	fold	Proceeds From Capped Call Confirmations Exchange Of Convertible Debt ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt	0	USD
CY2019	fold	Proceeds From Capped Call Confirmations Exchange Of Convertible Debt ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt	-19875000	USD
CY2018	fold	Proceeds From Capped Call Confirmations Exchange Of Convertible Debt ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt	0	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	42282000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	11476000	USD
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9144000	USD
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
CY2019	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	812000	USD
CY2018	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	3617000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	262858000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	217502000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	450775000	USD
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3830000	USD
CY2019	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1729000	USD
CY2018	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1518000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	19819000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	63968000	USD
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	31138000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	146343000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82375000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51237000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	166162000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	146343000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82375000	USD
CY2020	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	470000	USD
CY2019	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	19388000	USD
CY2018	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	0	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	24683000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	16966000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	7500000	USD
CY2020	fold	Contingent Consideration Paid In Stock ContingentConsiderationPaidInStock	0	USD
CY2019	fold	Contingent Consideration Paid In Stock ContingentConsiderationPaidInStock	9316000	USD
CY2018	fold	Contingent Consideration Paid In Stock ContingentConsiderationPaidInStock	0	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	985000	USD
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	106000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1865000	USD
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	10371000	USD
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	691000	USD
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1062000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2000000000.0	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company assessed the impact COVID-19 pandemic has had on its operations and financial results as of December 31, 2020 and through the issuance of this report. The Company’s analysis was informed by the facts and circumstances as they were known to the Company. This assessment considered the impact COVID-19 may have on financial estimates and assumptions that affect the reported amounts of assets and liabilities and revenue and expenses.</span></div>
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial instruments that are exposed to concentration of credit risk consist primarily of cash, cash equivalents, and marketable securities. The Company maintains its cash and cash equivalents in bank accounts, which, at times, exceed federally insured limits. The Company invests its marketable securities in high-quality commercial financial instruments. The Company has not recognized any losses from credit risks on such accounts during any of the periods presented. The Company believes it is not exposed to significant credit risk on its cash, cash equivalents, or marketable securities.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable related to its product sales of Galafold</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">®</span>. The Company's accounts receivable at December 31, 2020 have arisen from product sales primarily in Europe and the U.S. The Company will periodically assess the financial strength of its customers to establish allowances for anticipated losses, if any. For accounts receivable that have arisen from named patient sales, the payment terms are predetermined, and the Company evaluates the creditworthiness of each customer on a regular basis.
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	100000	USD
CY2020	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	260886000	USD
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	182237000	USD
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	91245000	USD
CY2020Q4	fold	Share Based Compensation Number Of Plans ShareBasedCompensationNumberOfPlans	1	plan
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	unit
CY2018Q3	fold	Number Of Gene Therapy Programs For Neurologic Ls Ds Developed NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped	10	program
CY2018Q3	fold	Number Of Gene Therapy Programs For Neurologic Ls Ds Developed NumberOfGeneTherapyProgramsForNeurologicLSDsDeveloped	10	program
CY2020Q4	us-gaap	Goodwill Goodwill	197800000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23000000.0	USD
CY2018Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	23000000.0	USD
CY2019	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2019Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	23000000.0	USD
CY2020	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2020Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	23000000.0	USD
CY2018Q4	us-gaap	Goodwill Goodwill	197800000	USD
CY2019	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	0	USD
CY2019Q4	us-gaap	Goodwill Goodwill	197800000	USD
CY2020	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	0	USD
CY2020Q4	us-gaap	Goodwill Goodwill	197800000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	163200000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	320000000.0	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	163240000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	163240000	USD
CY2020Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	483256000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	39000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	26000	USD
CY2020Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	483269000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	163240000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	163240000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	320016000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	39000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	26000	USD
CY2019Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	3506000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	320029000	USD
CY2020Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	483256000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	39000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	26000	USD
CY2020Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	483269000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	142837000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	142837000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	452502000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	255000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	17000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	452740000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	142837000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	142837000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	309665000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	255000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	17000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	309903000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities CashCashEquivalentsAndAvailableforsaleDebtSecurities	452502000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	255000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	17000	USD
CY2019Q4	fold	Cash Cash Equivalents And Availableforsale Debt Securities Fair Value Disclosure CashCashEquivalentsAndAvailableforsaleDebtSecuritiesFairValueDisclosure	452740000	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	9500000	USD
CY2020	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	USD
CY2019	us-gaap	Debt Securities Realized Gain Loss DebtSecuritiesRealizedGainLoss	0	USD
CY2020Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	124900000	USD
CY2019Q4	us-gaap	Debt Securities Available For Sale Unrealized Loss Position DebtSecuritiesAvailableForSaleUnrealizedLossPosition	42600000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	163240000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	142837000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	79749000	USD
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2922000	USD
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2626000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	166162000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	146343000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	82375000	USD
CY2020Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	5547000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	6544000	USD
CY2020Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	7693000	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3660000	USD
CY2020Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	6316000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	3837000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	100000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	19556000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	14041000	USD
CY2019Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	200000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	58350000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	65309000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	14487000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	17604000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	43863000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	47705000	USD
CY2020	us-gaap	Depreciation Depreciation	8400000	USD
CY2019	us-gaap	Depreciation Depreciation	4500000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3700000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	7832000	USD
CY2020Q4	fold	Accrued Contract Manufacturing And Contract Research Costs Current AccruedContractManufacturingAndContractResearchCostsCurrent	19617000	USD
CY2019Q4	fold	Accrued Contract Manufacturing And Contract Research Costs Current AccruedContractManufacturingAndContractResearchCostsCurrent	17800000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	23025000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	27156000	USD
CY2020Q4	fold	Accrued Program Fees AccruedProgramFees	16599000	USD
CY2019Q4	fold	Accrued Program Fees AccruedProgramFees	17016000	USD
CY2020Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	6550000	USD
CY2019Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	5196000	USD
CY2020Q4	us-gaap	Interest Payable Current InterestPayableCurrent	0	USD
CY2019Q4	us-gaap	Interest Payable Current InterestPayableCurrent	3679000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4000000	USD
CY2020Q4	fold	Accrued Sales Rebates And Chargebacks Current AccruedSalesRebatesAndChargebacksCurrent	12079000	USD
CY2019Q4	fold	Accrued Sales Rebates And Chargebacks Current AccruedSalesRebatesAndChargebacksCurrent	5900000	USD
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	11177000	USD
CY2019Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	7300000	USD
CY2020Q4	us-gaap	Deferred Credits And Other Liabilities Current DeferredCreditsAndOtherLiabilitiesCurrent	1500000	USD
CY2019Q4	us-gaap	Deferred Credits And Other Liabilities Current DeferredCreditsAndOtherLiabilitiesCurrent	1250000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2594000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2772000	USD
CY2020Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	96841000	USD
CY2019Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	99901000	USD
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2020Q4	fold	Common Stock Voting Rights For Each Share Held CommonStockVotingRightsForEachShareHeld	1	vote
CY2019Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	18700000	shares
CY2019Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	189000000.0	USD
CY2019Q1	fold	Contingent Consideration Milestone Payment ContingentConsiderationMilestonePayment	9000000.0	USD
CY2019Q2	fold	Debt Instrument Convertible Debt Exchange Agreement Aggregate Principal Amount DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount	247200000	USD
CY2019Q2	fold	Debt Instrument Convertible Debt Exchange Agreement Shares Authorized For Issuance DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance	44000000.0	shares
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2020Q4	us-gaap	Trading Securities TradingSecurities	4100000	USD
CY2019Q4	us-gaap	Trading Securities TradingSecurities	4400000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	49151000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	44430000	USD
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	29260000	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	324055000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	25825000	USD
CY2020Q4	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	4078000	USD
CY2020Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	29903000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	314270000	USD
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	22681000	USD
CY2019Q4	us-gaap	Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent	4419000	USD
CY2019Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	27100000	USD
CY2019Q1	fold	Milestone Payment Stock Issued As Consideration MilestonePaymentStockIssuedAsConsideration	9000000.0	USD
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	22681000	USD
CY2018Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	19700000	USD
CY2020	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-3144000	USD
CY2019	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings	-3297000	USD
CY2020	fold	Contingent Consideration Paid In Stock Adjustment ContingentConsiderationPaidInStockAdjustment	0	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	389254000	USD
CY2019Q4	us-gaap	Long Term Debt LongTermDebt	149505000	USD
CY2019Q2	fold	Debt Instrument Convertible Debt Exchange Agreement Aggregate Principal Amount DebtInstrumentConvertibleDebtExchangeAgreementAggregatePrincipalAmount	247200000	USD
CY2019	fold	Contingent Consideration Paid In Stock Adjustment ContingentConsiderationPaidInStockAdjustment	316000	USD
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	25825000	USD
CY2019Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	22681000	USD
CY2019Q2	fold	Debt Instrument Convertible Debt Exchange Agreement Shares Authorized For Issuance DebtInstrumentConvertibleDebtExchangeAgreementSharesAuthorizedForIssuance	44000000.0	shares
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
	fold	Debt Instrument Convertible Debt Exchange Agreement Accrued And Unpaid Interest DebtInstrumentConvertibleDebtExchangeAgreementAccruedAndUnpaidInterest	1300000	USD
CY2019	fold	Gain Loss On Extinguishment Of Debt Additional Paid In Capital GainLossOnExtinguishmentOfDebtAdditionalPaidInCapital	215000000.0	USD
CY2019	fold	Gain Loss On Extinguishment Of Debt Fair Value Of Common Shares Issued GainLossOnExtinguishmentOfDebtFairValueOfCommonSharesIssued	400000	USD
CY2019	fold	Gain Loss On Exchange Of Debt GainLossOnExchangeOfDebt	-40600000	USD
	fold	Proceeds From Capped Call Confirmations Exchange Of Convertible Debt ProceedsFromCappedCallConfirmationsExchangeOfConvertibleDebt	19900000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	6872000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	7189000	USD
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	11100000	USD
CY2019	us-gaap	Operating Lease Expense OperatingLeaseExpense	10800000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	9600000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	4900000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1700000	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	21800000	USD
CY2020	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	500000	USD
CY2019	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	19400000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	23296000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	33315000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	52476000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	60720000	USD
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.131
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	8549000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	195750000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	91078000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P19Y9M18D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P18Y2M12D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.130
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	8494000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	8691000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	8404000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	8371000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	153241000	USD
CY2020Q4	fold	Lessee Operating Lease Liability Tenant Incentives LesseeOperatingLeaseLiabilityTenantIncentives	28939000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	114335000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	52476000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9738000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	10787000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	10459000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	10809000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	10582000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	163266000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	215641000	USD
CY2019Q4	fold	Lessee Operating Lease Liability Tenant Incentives LesseeOperatingLeaseLiabilityTenantIncentives	28939000	USD
CY2019Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	125982000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	60720000	USD
CY2018	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	5700000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-365332000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-393955000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-309183000	USD
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.02
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	38045000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-39906000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-274254000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-355910000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-349089000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	6000	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	4163000	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	2877000	USD
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-100000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1410000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-984000	USD
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-155000	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-1415000	USD
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2598000	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	478000	USD
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-94000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.04
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.06
CY2020	fold	Effective Income Tax Rate Reconciliation Fair Value Of Contingent Consideration EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration	0
CY2019	fold	Effective Income Tax Rate Reconciliation Fair Value Of Contingent Consideration EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration	0
CY2018	fold	Effective Income Tax Rate Reconciliation Fair Value Of Contingent Consideration EffectiveIncomeTaxRateReconciliationFairValueOfContingentConsideration	-0.01
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.07
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.16
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.10
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.04
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.09
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0
CY2020	fold	Effective Income Tax Rate Reconciliation Nondeductible Expense Debt Conversion EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion	0
CY2019	fold	Effective Income Tax Rate Reconciliation Nondeductible Expense Debt Conversion EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion	0.01
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.23
CY2018	fold	Effective Income Tax Rate Reconciliation Nondeductible Expense Debt Conversion EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDebtConversion	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.29
CY2020	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	-1600000	USD
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.02
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.01
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.01
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.26
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.01
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2017Q4	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	4200000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	2329000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2020Q4	us-gaap	Liability For Uncertain Tax Positions Current LiabilityForUncertainTaxPositionsCurrent	0	USD
CY2020Q4	fold	Deferred Tax Assets Intellectual Property DeferredTaxAssetsIntellectualProperty	68209000	USD
CY2019Q4	fold	Deferred Tax Assets Intellectual Property DeferredTaxAssetsIntellectualProperty	46521000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	489000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	182651000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	141669000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	305876000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	286850000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	1912000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	2230000	USD
CY2020Q4	fold	Deferred Tax Assets Non Cash Stock Issue Non Current DeferredTaxAssetsNonCashStockIssueNonCurrent	17553000	USD
CY2019Q4	fold	Deferred Tax Assets Non Cash Stock Issue Non Current DeferredTaxAssetsNonCashStockIssueNonCurrent	19058000	USD
CY2020Q4	fold	Deferred Tax Assets Interest Carryforward Limitation DeferredTaxAssetsInterestCarryforwardLimitation	5655000	USD
CY2019Q4	fold	Deferred Tax Assets Interest Carryforward Limitation DeferredTaxAssetsInterestCarryforwardLimitation	2224000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	602435000	USD
CY2020Q4	fold	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	9235000	USD
CY2019Q4	fold	Deferred Tax Assets Leasing Arrangements DeferredTaxAssetsLeasingArrangements	6983000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	10855000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	13921000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	521785000	USD
CY2020Q4	fold	Deferred Tax Liabilities Business Acquisition DeferredTaxLiabilitiesBusinessAcquisition	4937000	USD
CY2019Q4	fold	Deferred Tax Liabilities Business Acquisition DeferredTaxLiabilitiesBusinessAcquisition	5051000	USD
CY2020Q4	fold	Deferred Tax Liabilities Royalty Payable DeferredTaxLiabilitiesRoyaltyPayable	68209000	USD
CY2019Q4	fold	Deferred Tax Liabilities Royalty Payable DeferredTaxLiabilitiesRoyaltyPayable	46521000	USD
CY2020Q4	fold	Deferred Tax Liabilities Convertible Notes DeferredTaxLiabilitiesConvertibleNotes	94000	USD
CY2019Q4	fold	Deferred Tax Liabilities Convertible Notes DeferredTaxLiabilitiesConvertibleNotes	653000	USD
CY2020Q4	fold	Deferred Tax Liabilities Advanced Research And Development Payments DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments	1776000	USD
CY2019Q4	fold	Deferred Tax Liabilities Advanced Research And Development Payments DeferredTaxLiabilitiesAdvancedResearchAndDevelopmentPayments	2611000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	3420000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	5643000	USD
CY2019Q4	fold	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	461306000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	528895000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	466357000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	4896000	USD
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	258867380	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	240421001	shares
CY2020Q4	fold	Deferred Tax Assets Liabilities Gross DeferredTaxAssetsLiabilitiesGross	523999000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	5051000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	528900000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	466400000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	62500000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-276852000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-356388000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-348995000	USD
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	185790021	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24129000	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25533000	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	63029000	shares
CY2020Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	60525000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	62353000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	67437000	USD
CY2020Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	70571000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-88948000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-52492000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-64011000	USD
CY2020Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-71401000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.20
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2019Q1	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	34046000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	44130000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	48768000	USD
CY2019Q4	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	55293000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-120299000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-84551000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-61809000	USD
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-89729000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.24
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.35

Files In Submission

Name	View Source	Status
0001178879-21-000004-index-headers.html	Edgar Link	pending
0001178879-21-000004-index.html	Edgar Link	pending
0001178879-21-000004.txt	Edgar Link	pending
0001178879-21-000004-xbrl.zip	Edgar Link	pending
exhibit21.htm	Edgar Link	pending
exhibit231.htm	Edgar Link	pending
exhibit311.htm	Edgar Link	pending
exhibit312.htm	Edgar Link	pending
exhibit321.htm	Edgar Link	pending
exhibit322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
fold-20201231.htm	Edgar Link	pending
fold-20201231.xsd	Edgar Link	pending
fold-20201231_cal.xml	Edgar Link	unprocessable
fold-20201231_def.xml	Edgar Link	unprocessable
fold-20201231_g1.jpg	Edgar Link	pending
fold-20201231_htm.xml	Edgar Link	completed
fold-20201231_lab.xml	Edgar Link	unprocessable
fold-20201231_pre.xml	Edgar Link	unprocessable
formofboardrestrictedstock.htm	Edgar Link	pending
formofboardstockoptionawar.htm	Edgar Link	pending
formofrestrictedstockunita.htm	Edgar Link	pending
formofstockoptionawardagre.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold

2020 Q4 Form 10-K Financial Statement

#000117887921000004 Filed on March 01, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD AMICUS THERAPEUTICS, INC. Stock $fold

2020 Q4 Form 10-K Financial Statement

#000117887921000004 Filed on March 01, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FOLD
AMICUS THERAPEUTICS, INC. Stock $fold